Document is current

Any future updates will be listed below

Disparities in receipt of 1-st line CDK4/6 inhibitors with endocrine therapy for treatment of hormone receptor positive, HER2 negative metastatic breast cancer in the real-world setting

Crossref DOI link: https://doi.org/10.1186/s13058-024-01902-w

Published Online: 2024-10-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark